MedTrace Logo

Drug Monitoring in Critically Ill Patients During Extracorporeal Life Support

NCT04127305 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-02-11

No results posted yet for this study

Summary

About 70% of critically ill patients require antiinfective therapy. Optimal antibiotic dosing is key to improve patient survival, reduce toxic effects and minimise the emergence of bacterial resistance. There is a growing body of evidence demonstrating the existence of significant changes in pharmacokinetics (PK) in intensive care patients, particularly those with extracorporeal therapy (extracorporeal membrane oxygenation (ECMO), continuous renal replacement therapy (CRRT)). To characterize the effects of extracorporal therapy for critically ill patients, we designed a prospective pilot observational study using a drug monitoring to derive relevant effects of extracorporeal therapy and clinical patient characteristics for the treatment with meropenem, teicoplanin, linezolid, piperacillin/tazobactam, levofloxacin and acyclovir.

Conditions

  • Drug Monitoring of Antiinfectives in Critically Ill Patients Receiving Extracorporeal Life Support

Interventions

OTHER

No Intervention

No Intervention

Sponsors & Collaborators

  • Goethe University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2021-12-31
Completion
2022-05-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04127305 on ClinicalTrials.gov